Climb Bio (NASDAQ:CLYM) outlined its clinical development strategy and upcoming data readouts during a fireside chat at H.C. Wainwright’s BioConnect Conference, with management emphasizing two biologic drug programs aimed at immune-mediated diseases, including nephrology and hematology indications.
H.C. Wainwright analyst Ram Selvaraju, who hosted the discussion, said his firm covers Climb Bio with a buy rating and a 12-month price target of $20 per share. Susan Altschuller, chief financial officer of Climb Bio, and Perrin Wilson, chief business officer, represented the company at the event.